

# Kenzo Tokunaga

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3652861/publications.pdf>

Version: 2024-02-01

82  
papers

6,815  
citations

147726

31  
h-index

74108

75  
g-index

90  
all docs

90  
docs citations

90  
times ranked

8816  
citing authors

#	ARTICLE	IF	CITATIONS
1	SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion. <i>Nature</i> , 2021, 599, 114-119.	13.7	1,041
2	Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity. <i>Nature</i> , 2022, 603, 706-714.	13.7	756
3	Modulation of TNF- $\alpha$ -converting enzyme by the spike protein of SARS-CoV and ACE2 induces TNF- $\alpha$ production and facilitates viral entry. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 7809-7814.	3.3	478
4	Attenuated fusogenicity and pathogenicity of SARS-CoV-2 Omicron variant. <i>Nature</i> , 2022, 603, 700-705.	13.7	447
5	Enhanced fusogenicity and pathogenicity of SARS-CoV-2 Delta P681R mutation. <i>Nature</i> , 2022, 602, 300-306.	13.7	428
6	Human APOBEC3F Is Another Host Factor That Blocks Human Immunodeficiency Virus Type 1 Replication. <i>Journal of Virology</i> , 2004, 78, 6073-6076.	1.5	416
7	SARS-CoV-2 D614G spike mutation increases entry efficiency with enhanced ACE2-binding affinity. <i>Nature Communications</i> , 2021, 12, 848.	5.8	389
8	HIV-1 Accessory Protein Vpu Internalizes Cell-surface BST-2/Tetherin through Transmembrane Interactions Leading to Lysosomes. <i>Journal of Biological Chemistry</i> , 2009, 284, 35060-35072.	1.6	197
9	All APOBEC3 family proteins differentially inhibit LINE-1 retrotransposition. <i>Nucleic Acids Research</i> , 2007, 35, 2955-2964.	6.5	182
10	The SARS-CoV-2 Lambda variant exhibits enhanced infectivity and immune resistance. <i>Cell Reports</i> , 2022, 38, 110218.	2.9	148
11	Successful Mouse Cloning of an Outbred Strain by Trichostatin A Treatment after Somatic Nuclear Transfer. <i>Journal of Reproduction and Development</i> , 2007, 53, 165-170.	0.5	141
12	SARS-CoV-2 B.1.617 Mutations L452R and E484Q Are Not Synergistic for Antibody Evasion. <i>Journal of Infectious Diseases</i> , 2021, 224, 989-994.	1.9	136
13	Early replication block of human immunodeficiency virus type 1 in monkey cells. <i>Journal of General Virology</i> , 1995, 76, 2723-2730.	1.3	123
14	MARCH8 inhibits HIV-1 infection by reducing virion incorporation of envelope glycoproteins. <i>Nature Medicine</i> , 2015, 21, 1502-1507.	15.2	112
15	Host restriction factors in retroviral infection: promises in virus-host interaction. <i>Retrovirology</i> , 2012, 9, 112.	0.9	88
16	Molecular Basis for Cell Tropism of CXCR4-Dependent Human Immunodeficiency Virus Type 1 Isolates. <i>Journal of Virology</i> , 2001, 75, 6776-6785.	1.5	86
17	HIV-1 Vpr Induces DNA Double-Strand Breaks. <i>Cancer Research</i> , 2006, 66, 627-631.	0.4	69
18	HIV-1 Proteases from Drug-Naive West African Patients Are Differentially Less Susceptible to Protease Inhibitors. <i>Clinical Infectious Diseases</i> , 2005, 41, 243-251.	2.9	67

#	ARTICLE	IF	CITATIONS
19	Membrane-associated RING-CH (MARCH) 8 mediates the ubiquitination and lysosomal degradation of the transferrin receptor. <i>Journal of Cell Science</i> , 2013, 126, 2798-809.	1.2	63
20	Intrinsic restriction activity by apolipoprotein B mRNA editing enzyme APOBEC1 against the mobility of autonomous retrotransposons. <i>Nucleic Acids Research</i> , 2011, 39, 5538-5554.	6.5	59
21	Super-rapid quantitation of the production of HIV-1 harboring a luminescent peptide tag. <i>Journal of Biological Chemistry</i> , 2020, 295, 13023-13030.	1.6	57
22	Interleukin-8-mediated Heterologous Receptor Internalization Provides Resistance to HIV-1 Infectivity. <i>Journal of Biological Chemistry</i> , 2003, 278, 15867-15873.	1.6	52
23	Characteristics of IFITM, the newly identified IFN-inducible anti-HIV-1 family proteins. <i>Microbes and Infection</i> , 2013, 15, 280-290.	1.0	52
24	Function of human immunodeficiency virus type 1 Vpu protein in various cell types. <i>Journal of General Virology</i> , 1995, 76, 2717-2722.	1.3	52
25	HIV-1 Vpr induces ATM-dependent cellular signal with enhanced homologous recombination. <i>Oncogene</i> , 2007, 26, 477-486.	2.6	50
26	Differential Anti-APOBEC3G Activity of HIV-1 Vif Proteins Derived from Different Subtypes. <i>Journal of Biological Chemistry</i> , 2010, 285, 35350-35358.	1.6	48
27	Amino Acid 36 in the Human Immunodeficiency Virus Type 1 gp41 Ectodomain Controls Fusogenic Activity: Implications for the Molecular Mechanism of Viral Escape from a Fusion Inhibitor. <i>Journal of Virology</i> , 2005, 79, 5996-6004.	1.5	46
28	Retroelements versus APOBEC3 family members: No great escape from the magnificent seven. <i>Frontiers in Microbiology</i> , 2012, 3, 275.	1.5	45
29	Membrane-associated RING-CH (MARCH) 1 and 2 are MARCH family members that inhibit HIV-1 infection. <i>Journal of Biological Chemistry</i> , 2019, 294, 3397-3405.	1.6	43
30	Epigenetic displacement of HP1 from heterochromatin by HIV-1 Vpr causes premature sister chromatid separation. <i>Journal of Cell Biology</i> , 2011, 194, 721-735.	2.3	39
31	MARCH8 inhibits viral infection by two different mechanisms. <i>ELife</i> , 2020, 9, .	2.8	37
32	Two N-Linked Glycosylation Sites in the V2 and C2 Regions of Human Immunodeficiency Virus Type 1 CRF01_AE Envelope Glycoprotein gp120 Regulate Viral Neutralization Susceptibility to the Human Monoclonal Antibody Specific for the CD4 Binding Domain. <i>Journal of Virology</i> , 2010, 84, 4311-4320.	1.5	35
33	An HIV-1 capsid binding protein TRIM11 accelerates viral uncoating. <i>Retrovirology</i> , 2016, 13, 72.	0.9	35
34	Expression of human immunodeficiency virus type 1 Nef antigen on the surface of acutely and persistently infected human T cells. <i>Vaccine</i> , 1993, 11, 1240-1246.	1.7	31
35	DNA damage enhances integration of HIV-1 into macrophages by overcoming integrase inhibition. <i>Retrovirology</i> , 2013, 10, 21.	0.9	26
36	Enhancement of human immunodeficiency virus type 1 infectivity by Nef is producer cell-dependent.. <i>Journal of General Virology</i> , 1998, 79, 2447-2453.	1.3	25

#	ARTICLE	IF	CITATIONS
37	Nucleolin and the Packaging Signal, $\Psi$ , Promote the Budding of Human Immunodeficiency Virus Type 1 (HIV-1). <i>Microbiology and Immunology</i> , 2004, 48, 111-118.	0.7	22
38	Structural Basis for the Antiviral Activity of BST-2/Tetherin and Its Viral Antagonism. <i>Frontiers in Microbiology</i> , 2011, 2, 250.	1.5	22
39	Homeostatically Maintained Resting Naive CD4+ T Cells Resist Latent HIV Reactivation. <i>Frontiers in Microbiology</i> , 2016, 7, 1944.	1.5	22
40	Altered cell tropism and cytopathicity of feline immunodeficiency viruses in two different feline CD4-positive, CD8-negative cell lines. <i>Journal of Virology</i> , 1992, 66, 3893-3898.	1.5	22
41	Naturally occurring accessory gene mutations lead to persistent human immunodeficiency virus type 1 infection of CD4-positive T cells. <i>Journal of Virology</i> , 1995, 69, 7507-7518.	1.5	22
42	The HIV-1 accessory protein Vpr induces the degradation of the anti-HIV-1 agent APOBEC3G through a VprBP-mediated proteasomal pathway. <i>Virus Research</i> , 2015, 195, 25-34.	1.1	21
43	Genotypic Characterization of CRF01_AE <i>env</i> Genes Derived from Human Immunodeficiency Virus Type 1-Infected Patients Residing in Central Thailand. <i>AIDS Research and Human Retroviruses</i> , 2009, 25, 229-236.	0.5	20
44	Anti-APOBEC3G Activity of HIV-1 Vif Protein Is Attenuated in Elite Controllers. <i>Journal of Virology</i> , 2015, 89, 4992-5001.	1.5	20
45	Inhibition of Human Immunodeficiency Virus Type 1 Virion Entry by Dominant-Negative Hck. <i>Journal of Virology</i> , 1998, 72, 6257-6259.	1.5	20
46	Tristetraprolin inhibits HIV-1 production by binding to genomic RNA. <i>Microbes and Infection</i> , 2006, 8, 2647-2656.	1.0	19
47	Phenotypic studies on recombinant human immunodeficiency virus type 1 (HIV-1) containing CRF01_AE <i>env</i> gene derived from HIV-1-infected patient, residing in central Thailand. <i>Microbes and Infection</i> , 2009, 11, 334-343.	1.0	19
48	APOBEC3G Oligomerization Is Associated with the Inhibition of Both Alu and LINE-1 Retrotransposition. <i>PLoS ONE</i> , 2013, 8, e84228.	1.1	19
49	Generation and Characterization of a Host Cell-Dependent gag Gene Mutant of Human Immunodeficiency Virus Type 1. <i>Virology</i> , 1995, 212, 251-254.	1.1	17
50	Growth ability of auxiliary gene mutants of human immunodeficiency virus types 1 and 2 in unstimulated peripheral blood mononuclear cells. <i>Archives of Virology</i> , 1997, 142, 177-181.	0.9	17
51	CRISPR-mediated activation of endogenous BST-2/tetherin expression inhibits wild-type HIV-1 production. <i>Scientific Reports</i> , 2019, 9, 3134.	1.6	17
52	Impact of Amino Acid Variations in Gag and Protease of HIV Type 1 CRF01_AE Strains on Drug Susceptibility of Virus to Protease Inhibitors. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2009, 52, 320-328.	0.9	15
53	Sites of Action of HIV-1 Vpu in BST-2/Tetherin Downregulation. <i>Current HIV Research</i> , 2012, 10, 283-291.	0.2	15
54	MARCH8 Targets Cytoplasmic Lysine Residues of Various Viral Envelope Glycoproteins. <i>Microbiology Spectrum</i> , 2022, 10, e0061821.	1.2	15

#	ARTICLE	IF	CITATIONS
55	Requirement of Nef for HIV-1 infectivity is biased by the expression levels of Env in the virus-producing cells and CD4 in the target cells. Archives of Virology, 2001, 146, 1739-1751.	0.9	14
56	Inhibitory function of adapter-related protein complex 2 alpha 1 subunit in the process of nuclear translocation of human immunodeficiency virus type 1 genome. Virology, 2008, 373, 171-180.	1.1	14
57	Direct internalization of cell-surface BST-2/tetherin by the HIV-1 accessory protein Vpu. Communicative and Integrative Biology, 2010, 3, 366-369.	0.6	14
58	Human topoisomerase I promotes HIV-1 proviral DNA synthesis: Implications for the species specificity and cellular tropism of HIV-1 infection. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 8442-8447.	3.3	13
59	Critical Contribution of Tyr15 in the HIV-1 Integrase (IN) in Facilitating IN Assembly and Nonenzymatic Function through the IN Precursor Form with Reverse Transcriptase. Journal of Virology, 2017, 91, .	1.5	13
60	Superinfection of a Defective Human Immunodeficiency Virus Type 1 Provirus-Carrying T Cell Clone with <i>vif</i> or <i>vpu</i> Mutants Gives Cytopathic Virus Particles by Homologous Recombination. AIDS Research and Human Retroviruses, 1995, 11, 45-53.	0.5	12
61	Identification of the suppressive factors for human immunodeficiency virus type-1 replication using the siRNA mini-library directed against host cellular genes. Biochemical and Biophysical Research Communications, 2007, 359, 729-734.	1.0	11
62	Producer Cell-Dependent Requirement of the Nef Protein for Efficient Entry of HIV-1 into Cells. Biochemical and Biophysical Research Communications, 1998, 250, 565-568.	1.0	10
63	The Cellular Kinase Binding Motifs (PxxP and RR) in Human Immunodeficiency Virus Type 1 Nef Protein Are Dispensable for Producer-Cell-Dependent Enhancement of Viral Entry. Virology, 1999, 257, 285-289.	1.1	10
64	Interleukin-4 Upregulates T-tropic Human Immunodeficiency Virus Type 1 Transcription in Primary CD4 <sup>+</sup> CD38 <sup>+</sup> T-lymphocyte Subset. Microbiology and Immunology, 2005, 49, 155-165.	0.7	9
65	Impact of amino acid substitutions in the V2 and C2 regions of human immunodeficiency virus type 1 CRF01_AE envelope glycoprotein gp120 on viral neutralization susceptibility to broadly neutralizing antibodies specific for the CD4 binding site. Retrovirology, 2014, 11, 32.	0.9	9
66	Functional analysis of human spuma retrovirus genome. Virus Genes, 1995, 11, 15-20.	0.7	8
67	Intracellular Logistics of BST-2/Tetherin. Current HIV Research, 2012, 10, 321-326.	0.2	8
68	MARCH8: the tie that binds to viruses. FEBS Journal, 2022, 289, 3642-3654.	2.2	8
69	Aromatic Side Chain at Position 412 of SERINC5 Exerts Restriction Activity toward HIV-1 and Other Retroviruses. Journal of Virology, 2021, 95, e0063421.	1.5	8
70	Premature sister chromatid separation in HIV-1-infected peripheral blood lymphocytes. Aids, 2005, 19, 1434-1438.	1.0	6
71	Combined analysis of cell growth and apoptosis-regulating proteins in HPVs associated anogenital tumors. BMC Cancer, 2010, 10, 118.	1.1	6
72	Increased anti-HIV-1 activity of CD4 CDR3-related synthetic peptides by scrambling and further structural modifications, including d-isomerization and dimerization. FEBS Letters, 1993, 330, 117-121.	1.3	5

#	ARTICLE	IF	CITATIONS
73	Identification of SNF2h, a Chromatin-Remodeling Factor, as a Novel Binding Protein of Vpr of Human Immunodeficiency Virus Type 1. <i>Journal of NeuroImmune Pharmacology</i> , 2011, 6, 177-187.	2.1	5
74	Rev-dependency of expression of human immunodeficiency virus type 1 gag and env genes. <i>FEBS Letters</i> , 1995, 365, 141-145.	1.3	4
75	Phenotypic and Genotypic Co-receptor Tropism Testing in HIV-1 Epidemic Region of Tanzania Where Multiple Non-B Subtypes Co-circulate. <i>Frontiers in Microbiology</i> , 2021, 12, 703041.	1.5	4
76	Maintenance of high virus load even after seroconversion in newborn cats acutely infected with feline immunodeficiency virus. <i>Vaccine</i> , 1995, 13, 1393-1398.	1.7	3
77	Functionality of chimeric Rev proteins of HIV/SIV. <i>Virus Genes</i> , 1995, 11, 11-14.	0.7	2
78	Evaluation of telomerase activity in non-genital Bowen's disease. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2009, 23, 668-672.	1.3	2
79	The role of lysine residue at amino acid position 165 of human immunodeficiency virus type 1 CRF01_AE Gag in reducing viral drug susceptibility to protease inhibitors. <i>Virology</i> , 2010, 405, 129-138.	1.1	2
80	Membrane-associated RING-CH (MARCH) 8 protein inhibits HIV-1 infection. <i>Retrovirology</i> , 2013, 10, .	0.9	2
81	Transgenic expression of the human LEDGF/p75 gene relieves the species barrier against HIV-1 infection in mouse cells. <i>Frontiers in Microbiology</i> , 2013, 4, 377.	1.5	1
82	Editorial: HIV-1 Vpu and BST-2/Tetherin: Enemies at the Gates. <i>Current HIV Research</i> , 2012, 10, 275-276.	0.2	0